Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits

7/11/24 9:01:05 AM ET

$MYGN

$PSNL

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Medical Specialities

Health Care

Get the next $MYGN alert in real time by email

Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits

Get the next $MYGN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MYGN
$PSNL

Company	Date	Price Target	Rating	Analyst
Myriad Genetics Inc. $MYGN	9/19/2024	$32.00	Equal-Weight	Morgan Stanley
Myriad Genetics Inc. $MYGN	8/28/2024	$35.00	Overweight	Wells Fargo
Myriad Genetics Inc. $MYGN	6/27/2024	$29.00	Sector Outperform	Scotiabank
Myriad Genetics Inc. $MYGN	6/3/2024	$20.00	Underperform	Jefferies
Myriad Genetics Inc. $MYGN	5/8/2024	$25.00 → $35.00	Market Perform → Outperform	Leerink Partners
Myriad Genetics Inc. $MYGN	12/21/2023	$23.00	Neutral	Piper Sandler
Myriad Genetics Inc. $MYGN	12/19/2023	$20.00	Equal Weight	Wells Fargo
Myriad Genetics Inc. $MYGN	12/14/2023	$23.00	Buy	Guggenheim

More analyst ratings

$MYGN
$PSNL
Leadership Updates

Live Leadership Updates

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
SALT LAKE CITY, July 31, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Jennifer Fox as Chief Legal Officer, effective September 3, 2024. Fox brings nearly two decades of legal experience in the life sciences sector. Her expertise spans intellectual property, litigation, and regulatory matters, gained through roles in both in-house and private practice settings at industry-leading companies. As Chief Legal Officer, Fox's responsibilities will encompass a wide range of areas, including support and counsel for all legal affairs, intellectual property, patent protection, mergers and acquis
7/31/24 8:50:00 AM ET
$MYGN
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women's Health
SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women's health business unit, effective immediately. Dr. Reed brings nearly 15 years of clinical and academic experience rooted in genetics and obstetrics/gynecology to Myriad. In her new role, she will support internal and external efforts to increase access to, and equity around, genetic testing throughout a woman's health journey including family planning, pregnancy management and hereditary cancer risk assessment. "We're thrilled to welcome Dallas
2/15/24 4:05:00 PM ET
$MYGN
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024. Dr. Daneker brings more than 30 years of oncology and precision medicine experience deeply rooted in providing accessible and equitable oncology care for all patients. In his new role, he will be responsible for leading the commercial and clinical strategy to advance Myriad's oncology portfolio, which currently offers germline testing, tumor profiling and companion diagnostic options, including homologous recombinat
1/30/24 5:00:00 PM ET
$MYGN
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care

Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on payor coverage and revenue cycle initiatives.Third quarter GAAP net loss improved to $22.1 million from a loss of $61.3 million in the third quarter of 2023 on improved revenue, gross margins and disciplined management of operating expenses. Third quarter adjusted EBITDA increased to $14.1 million from $1.4 million in third quarter of 2023.Third quarter GAAP loss per share improved to $(0.24) from $(0.75) in the third quarter of 2023; adjusted earnings (loss) per share improved to $0.06 from ($0.03) in the third quarter of 2023.Updated 2024 financial
11/7/24 4:05:00 PM ET
$MYGN
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Personalis Reports Third Quarter 2024 Financial Results
41% Year-over-Year Increase in Revenue Driven by Strong Biopharma Growth of 96% Raising 2024 Revenue Guidance Due to Accelerating Growth Cash Balance of $143.7 Million Extends Expected Runway Into First-Half of 2027 Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2024, and provided recent business accomplishments. Recent Business Accomplishments Raised approximately $35.0 million in net financing proceeds from Tempus AI, Inc. (Tempus), consisting of $18.4 million from Tempus' exercise of all its common stock warrants, at an average price of $2.00 per share, and $16.6 millio
11/6/24 4:01:00 PM ET
$PSNL
Medical Specialities
Health Care
Myriad Genetics Comments on UnitedHealthcare's Updated Medical Policy for Pharmacogenetic Testing
SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, under its commercial and individual exchange benefit plans, effective January 1st, 2025. After initial review of the updated policy, the company strongly disagrees with UnitedHealthcare's inclusion of GeneSight in its decision to change its coverage policy of multi-gene panels based on its rationale that there is insufficient evidence of efficacy to support coverag
11/4/24 8:39:37 AM ET
$MYGN
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care

Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies. Myriad's gold-standard Genomic Instability Score (GIS) to determine Homologous Recombination Deficiency (HRD) will be reported for all samples analyzed with Illumina's updated research assay, TruSight™ Oncology 500 v2 (TSO 500 v2). Previously, GIS to determine HRD was only available as a separate product. As a result, a broad array of cancer types will receive GIS results and their HRD status. "We are pleased to expand o
11/20/24 4:30:00 PM ET
$ILMN
$MYGN
Medical Specialities
Health Care
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Personalis to Participate at Upcoming Investor Conferences
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following investor conferences: Piper Sandler 36th Annual Healthcare Conference Date: Tuesday, December 3, 2024 Fireside Chat Time: 12:30 pm Eastern Time Location: The Lotte New York Palace in New York, NY TD Cowen Diagnosing Tomorrow: Tools & Technologies for the Next Decade Date: Thursday, December 12, 2024 Panel Topic: MRD - The Future Tech Stack Panel Time: 1:30 pm Eastern Time Location: One Vanderbilt in New York, NY About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthro
11/20/24 4:01:00 PM ET
$PSNL
Medical Specialities
Health Care
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
SALT LAKE CITY, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced that the Prequel® Prenatal Screen is now available at eight weeks into pregnancy. Enabled by its AMPLIFY™ technology, Prequel is the first and only prenatal cell-free DNA (cfDNA) screen available at eight-weeks gestational age. "Previously, I would schedule my patients to come in at eight weeks for their first prenatal appointment; then, I would ask them to come back two weeks later to do a Prequel screen. Now that Prequel can be performed at eight weeks, patients have the opportunity to complete all baseline lab work during that initial care
11/19/24 8:00:00 AM ET
$MYGN
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care

Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits

Chat with this insight

Recent Analyst Ratings for $MYGN$PSNL

$MYGN$PSNL Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Myriad Genetics Inc.

Amendment: SEC Form SC 13G/A filed by Personalis Inc.

SEC Form SC 13G filed by Personalis Inc.

$MYGN$PSNL Leadership Updates

Live Leadership Updates

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women's Health

Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

$MYGN$PSNL Financials

Live finance-specific insights

$MYGN$PSNL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance

Personalis Reports Third Quarter 2024 Financial Results

Myriad Genetics Comments on UnitedHealthcare's Updated Medical Policy for Pharmacogenetic Testing

CFO AND COO Tachibana Aaron sold $4,954 worth of shares (1,307 units at $3.79), decreasing direct ownership by 0.75% to 173,963 units (SEC Form 4)

SVP and Chief Legal Officer Moore Stephen Michael sold $6,416 worth of shares (1,693 units at $3.79), decreasing direct ownership by 2% to 67,388 units (SEC Form 4)

CHIEF MEDICAL OFFICER AND EVP Chen Richard sold $3,491 worth of shares (921 units at $3.79), decreasing direct ownership by 0.71% to 128,720 units (SEC Form 4)

$MYGN$PSNL SEC Filings

SEC Form 10-Q filed by Myriad Genetics Inc.

Myriad Genetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Personalis Inc.

$MYGN$PSNL Market Insights

Live Market Insights

Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits

Myriad Genetics Secures Second Patent To Enhance Tumor-Informed High-Definition Molecular Residual Disease (MRD) Assay

Personalis 13D Filing Shows Tempus AI Reported A 15.1% Stake In The Co As Of July 3, 2024

$MYGN$PSNL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Morgan Stanley initiated coverage on Myriad Genetics with a new price target

Wells Fargo initiated coverage on Myriad Genetics with a new price target

Scotiabank initiated coverage on Myriad Genetics with a new price target

$MYGN$PSNL Press Releases

Fastest customizable press release news feed in the world

$MYGN$PSNL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

Personalis to Participate at Upcoming Investor Conferences

Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy

Myers Woodrow A Jr bought $16,700 worth of shares (10,000 units at $1.67), increasing direct ownership by 62% to 26,116 units (SEC Form 4)

Recent Analyst Ratings for
$MYGN
$PSNL

$MYGN
$PSNL
Large Ownership Changes

$MYGN
$PSNL
Leadership Updates

$MYGN
$PSNL
Financials

$MYGN
$PSNL
Insider Trading

$MYGN
$PSNL
SEC Filings

$MYGN
$PSNL
Market Insights

$MYGN
$PSNL
Analyst Ratings

$MYGN
$PSNL
Press Releases

$MYGN
$PSNL
Insider Purchases